Royalty Pharma plc (RPRX) Stock Forecast
RPRX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 8 analysts
- Price target
- $65.38 average of analyst targets
- Upside to target
- +7.2% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $1.18
- 52-week range
- $36.41 – $63.96
RPRX analyst ratings
8 analystsNumber of analysts at each rating.
RPRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RPRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.18 | $1.15 | $1.22 | $1.17 | +0.6% | 6 |
| Current fiscal year (2026) | $5.32 | $5.17 | $5.44 | $4.83 | +10.2% | 6 |
| Next fiscal year (2027) | $5.80 | $5.31 | $6.23 | $5.32 | +9.0% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RPRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $884.8M | $878.8M | $891.5M | +8.7% | 4 |
| Current fiscal year (2026) | $3.50B | $3.47B | $3.56B | +7.7% | 5 |
| Next fiscal year (2027) | $3.82B | $3.76B | $3.97B | +9.0% | 5 |
RPRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RPRX revenue: reported and forecast
RPRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.14 | $1.16 | $1.18 | $1.18 | $1.18 | +3.7% | 1 up · 1 down |
| Current fiscal year (2026) | $5.21 | $5.31 | $5.34 | $5.34 | $5.32 | +2.2% | 1 up · 1 down |
| Next fiscal year (2027) | $5.56 | $5.68 | $5.73 | $5.73 | $5.80 | +4.3% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RPRX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RPRX beat in 11 of 12.
What analysts expect from RPRX
8 analysts cover Royalty Pharma; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $65.38, 7.2% above the latest close of $60.96. Analysts expect earnings of $5.32 per share for 2026, +10.2% from a year earlier. For 2027 the average estimate is $5.80 per share on revenue of $3.8 billion. Royalty Pharma beat the EPS estimate in 11 of the last 12 quarters.
Related: RPRX income statement, RPRX key metrics, RPRX chart. See the RPRX stock overview for the latest quote and news.
RPRX forecast FAQ
What is Royalty Pharma's price target?
The average analyst price target for Royalty Pharma is $65.38, 7.2% above the latest close of $60.96.
Is Royalty Pharma a buy, hold or sell?
Of 8 analysts covering Royalty Pharma, 5 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Royalty Pharma's EPS forecast?
Analysts forecast $5.32 per share for 2026 (range $5.17 to $5.44); for 2027 the estimate is $5.80.
What is Royalty Pharma's revenue forecast?
The average revenue estimate for 2026 is $3.5 billion, growth of 7.7%; for 2027 it is $3.8 billion.
When does Royalty Pharma report earnings?
Royalty Pharma is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 before the market opens; the EPS estimate is $1.18.
Does Royalty Pharma usually beat earnings estimates?
Royalty Pharma reported EPS at or above the analyst estimate in 11 of the last 12 quarters.